VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

Stage IA/IB MF-CTCL is routinely managed by
qualified skin experts1

Mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) is a difficult to diagnose, slowly progressing form of cancer that appears on skin1-3

Example of Stage IA/IB MF-CTCL as Patches

Stage IA/Patch

Example of Stage IA/IB MF-CTCL as Plaques

Stage IB/Plaque

Example of Stage IA/IB MF-CTCL as Hypopigmentation

Stage IA/IB/Hypopigmentation

Actual Stage IA/IB MF-CTCL patient examples.

Early stage MF-CTCL patients may present with symptoms that often resemble, but are not, other inflammatory skin conditions such as psoriasis, eczema-like rashes, and non-specific dermatitis1,2

These other skin conditions are not treated by VALCHLOR.

Example of lesions that are not MF-CTCL

Non-MF-CTCL lesions

If your patients with Stage IA/IB MF-CTCL have received prior treatment such as topical corticosteroids, topical imiquimod, or phototherapy, it may be time for VALCHLOR.

Man (not an actual patient)

Key risk factors for MF-CTCL

Common patient characteristics (not limited to)2:

Age: 55 to 60 years

Gender: Male

Race: African-American

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for diagnosis4

  • Biopsy of suspicious skin sites
  • Review of a sufficient number of slides and/or at least one paraffin block representative of the lesion by a pathologist with expertise in the diagnosis of CTCLs
  • Immunohistochemistry panel of skin biopsy
  • Molecular analysis to detect clonal T-cell antigen receptor (TCR) gene rearrangement or other assessment of clonality